Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC By Ogkologos - June 25, 2025 580 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus... February 11, 2025 FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer... January 10, 2025 What to Know About Cancer Care and Research for People 65+:... February 28, 2023 Touching a nerve: How neuroscience could advance our understanding of cancer December 1, 2021 Load more HOT NEWS FDA Grants Accelerated Approval to Tafasitamab-cxix for DLBCL A Combination of Atezolizumab and Enzalutamide Does Not Improve Overall Survival... What My Mother’s Cancer Diagnosis Taught Me About Supporting a Loved... After Being Told a Lump Was Benign, Teenager Learns She Has...
